Limits...
miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers.

Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ - J Cancer (2016)

Bottom Line: Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells.MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells.Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Medical Biotechnology and Laboratory science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan;

ABSTRACT
Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells. MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells. The dysregulation of miRNA may contribute to numerous human disorders, including cancer. Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis. Here, we summarize the current knowledge concerning miR-196 family in cancers. This review includes miR-196 gene structure and aberrant expression in various cancers, and current understanding of numerous functions and regulatory targets of miR-196 in specific cancers. Since miR-196 are consistently found over-expressed in digestive tract cancer tissues, we also reviewed the clinical significance and potential applications of miR-196 in these cancers. We highlight that miR-196 may serve as an emerging cancer biomarker for digestive tract cancers.

No MeSH data available.


Related in: MedlinePlus

Elevation of miR-196b levels in the plasma of patients with digestive tract cancer. (n.s.: no statistical significance compared to normal group Mann-Whitney test, ***: P < 0.001 compared to normal group Mann-Whitney test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4829550&req=5

Figure 1: Elevation of miR-196b levels in the plasma of patients with digestive tract cancer. (n.s.: no statistical significance compared to normal group Mann-Whitney test, ***: P < 0.001 compared to normal group Mann-Whitney test).

Mentions: As stated above, miR-196 is elevated in the blood of patients with several types of digestive tract cancers. However, these results were obtained from various investigators who used different assay protocols which may lead to possible bias. To assess the diagnostic potential, we compared the miR-196b level in the plasma from healthy individuals and from patients with several types of cancers, including nasopharyngeal, oral, esophageal, gastric, colorectal and lung cancers. The results are shown in Figure 1. MiR-196b was substantial increased in digestive tract cancer patients, with an average elevation of 3.7- to 25.6-fold (P < 0.001 for all). The detection power of miR-196b for each cancer is summarized in Table 4 (Youden Index 69). Such high ability to discriminate between healthy individuals and cancer patients indicates that miR-196b may serve as a powerful circulating tumor marker for the detection of digestive tract cancers.


miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers.

Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ - J Cancer (2016)

Elevation of miR-196b levels in the plasma of patients with digestive tract cancer. (n.s.: no statistical significance compared to normal group Mann-Whitney test, ***: P < 0.001 compared to normal group Mann-Whitney test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4829550&req=5

Figure 1: Elevation of miR-196b levels in the plasma of patients with digestive tract cancer. (n.s.: no statistical significance compared to normal group Mann-Whitney test, ***: P < 0.001 compared to normal group Mann-Whitney test).
Mentions: As stated above, miR-196 is elevated in the blood of patients with several types of digestive tract cancers. However, these results were obtained from various investigators who used different assay protocols which may lead to possible bias. To assess the diagnostic potential, we compared the miR-196b level in the plasma from healthy individuals and from patients with several types of cancers, including nasopharyngeal, oral, esophageal, gastric, colorectal and lung cancers. The results are shown in Figure 1. MiR-196b was substantial increased in digestive tract cancer patients, with an average elevation of 3.7- to 25.6-fold (P < 0.001 for all). The detection power of miR-196b for each cancer is summarized in Table 4 (Youden Index 69). Such high ability to discriminate between healthy individuals and cancer patients indicates that miR-196b may serve as a powerful circulating tumor marker for the detection of digestive tract cancers.

Bottom Line: Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells.MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells.Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Medical Biotechnology and Laboratory science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan;

ABSTRACT
Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells. MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells. The dysregulation of miRNA may contribute to numerous human disorders, including cancer. Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis. Here, we summarize the current knowledge concerning miR-196 family in cancers. This review includes miR-196 gene structure and aberrant expression in various cancers, and current understanding of numerous functions and regulatory targets of miR-196 in specific cancers. Since miR-196 are consistently found over-expressed in digestive tract cancer tissues, we also reviewed the clinical significance and potential applications of miR-196 in these cancers. We highlight that miR-196 may serve as an emerging cancer biomarker for digestive tract cancers.

No MeSH data available.


Related in: MedlinePlus